Cantero-Fortiz Y, Boada M
Front Neurol. 2024; 15:1439125.
PMID: 39539666
PMC: 11558529.
DOI: 10.3389/fneur.2024.1439125.
Schoofs H, Schmit J, Rink L
Molecules. 2024; 29(13).
PMID: 38999082
PMC: 11243279.
DOI: 10.3390/molecules29133130.
Manjunatha R, Habib S, Sangaraju S, Yepez D, Grandes X
Cureus. 2022; 14(5):e24895.
PMID: 35706718
PMC: 9187186.
DOI: 10.7759/cureus.24895.
Manoharan I, Swafford D, Shanmugam A, Patel N, Prasad P, Thangaraju M
J Immunol. 2021; 207(5):1428-1436.
PMID: 34348977
PMC: 8415100.
DOI: 10.4049/jimmunol.2100010.
Orian J, DSouza C, Kocovski P, Krippner G, Hale M, Wang X
Front Immunol. 2021; 12:620963.
PMID: 33679764
PMC: 7933211.
DOI: 10.3389/fimmu.2021.620963.
Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated from Newly Diagnosed and IFN-ß-Treated MS Patients.
Navabi F, Shaygannejad V, Abbasirad F, Vaez E, Hosseininasab F, Kazemi M
Inflammation. 2018; 42(1):54-63.
PMID: 30178232
DOI: 10.1007/s10753-018-0872-x.
Comparison of Brain Atrophy, Cognition and Optical Coherence Tomography Results Between Multiple Sclerosis Patients and Healthy Controls.
Yurtogullari S, Taskapilioglu O, Ozturk B, Bilgic B, Hakyemez B, Turkes N
Noro Psikiyatr Ars. 2018; 55(1):3-8.
PMID: 30042634
PMC: 6045796.
DOI: 10.29399/npa.12534.
Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate.
Mayer L, Fink M, Sammarco C, Laing L
Drug Saf. 2017; 41(4):347-356.
PMID: 29218681
DOI: 10.1007/s40264-017-0621-3.
Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis.
Wetzels S, Wouters K, Schalkwijk C, Vanmierlo T, Hendriks J
Int J Mol Sci. 2017; 18(2).
PMID: 28212304
PMC: 5343955.
DOI: 10.3390/ijms18020421.
Blockade of the kinin B1 receptor affects the cytokine/chemokine profile in rat brain subjected to autoimmune encephalomyelitis.
Podsiadlo K, Sulkowski G, Dabrowska-Bouta B, Struzynska L
Inflammopharmacology. 2017; 25(4):459-469.
PMID: 28160128
DOI: 10.1007/s10787-017-0312-9.
High fat diet exacerbates neuroinflammation in an animal model of multiple sclerosis by activation of the Renin Angiotensin system.
Timmermans S, Bogie J, Vanmierlo T, Lutjohann D, Stinissen P, Hellings N
J Neuroimmune Pharmacol. 2013; 9(2):209-17.
PMID: 24068577
DOI: 10.1007/s11481-013-9502-4.
The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models.
Krementsov D, Thornton T, Teuscher C, Rincon M
Mol Cell Biol. 2013; 33(19):3728-34.
PMID: 23897428
PMC: 3811866.
DOI: 10.1128/MCB.00688-13.
The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis.
Faraco G, Cavone L, Chiarugi A
Mol Med. 2011; 17(5-6):442-7.
PMID: 21373721
PMC: 3105147.
DOI: 10.2119/molmed.2011.00077.
Early stage and long term treatment of multiple sclerosis with interferon-beta.
Applebee A, Panitch H
Biologics. 2009; 3:257-71.
PMID: 19707414
PMC: 2726076.
Absence of the cellular prion protein exacerbates and prolongs neuroinflammation in experimental autoimmune encephalomyelitis.
Tsutsui S, Hahn J, Johnson T, Ali Z, Jirik F
Am J Pathol. 2008; 173(4):1029-41.
PMID: 18815152
PMC: 2543071.
DOI: 10.2353/ajpath.2008.071062.
Role of HMG-CoA reductase inhibitors in neurological disorders : progress to date.
Reiss A, Wirkowski E
Drugs. 2007; 67(15):2111-20.
PMID: 17927279
DOI: 10.2165/00003495-200767150-00001.
Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis.
Kumasaka R, Nakamura N, Shirato K, Fujita T, Murakami R, Shimada M
Clin Exp Nephrol. 2006; 10(3):222-5.
PMID: 17009081
DOI: 10.1007/s10157-006-0424-9.
Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.
Noorbakhsh F, Tsutsui S, Vergnolle N, Boven L, Shariat N, Vodjgani M
J Exp Med. 2006; 203(2):425-35.
PMID: 16476770
PMC: 2118197.
DOI: 10.1084/jem.20052148.
N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats.
Stanislaus R, Gilg A, Singh A, Singh I
J Autoimmune Dis. 2005; 2(1):4.
PMID: 15869713
PMC: 1097751.
DOI: 10.1186/1740-2557-2-4.
What do we know about the mechanism of action of disease-modifying treatments in MS?.
Hartung H, Bar-Or A, Zoukos Y
J Neurol. 2004; 251 Suppl 5:v12-v29.
PMID: 15549350
DOI: 10.1007/s00415-004-1504-y.